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The activation of the classical renin–angiotensin aldosterone sys-
tem (RAAS) is known to be involved in the regulation of blood
volume and blood pressure and plays an important role in car-
diovascular pathology including hypertension and heart failure.
Evidence is now available that independently of the classical RAAS,
several RAAS components are expressed in cells from different
organs including the heart and kidney and are able to change
important physiological properties like cell communication, heart
excitability, and activation of ionic channels and cell volume when
applied locally to the cells (1) or systemically, independently of
blood pressure. In cardiac cells, swelling induced by angiotensin
II (Ang II), is counteracted by angiotensin (1–7) [Ang (1–7)] with
consequent decrease of swelling-dependent chloride current help-
ing the re-establishment of cell volume (2). Recently, it was found
that Ang (1–7) re-establishes cell communication impaired by cell
swelling in cardiac muscle raising the possibility of a beneficial
effect of the hexapeptide during myocardial ischemia (3). These
findings have important clinical implications (1, 4) and represent
a novel and fruitful pathway to be followed to better understand
the role of the RAAS in different pathological conditions. Fur-
thermore, they offer the opportunity for the development of new
therapeutic agents.
Although studies performed on transgenic animals generated
controversial results, evidence is available that the overexpression
of some components of RAAS like Ang II on cardiac muscle,
elicit ventricular hypertrophy independently of changes in arte-
rial blood pressure (5). Furthermore, the identification of some
of the RAAS components inside the cell including the nucleus
and mitochondria (6–8) and the results achieved dialyzing Ang II
or renin intracellularly (1, 7), supports the notion that there is an
intracellular component with functional properties (the intracrine
effect) (1, 7). In arterial myocytes from vascular resistance vessels,
for instance, intracellular Ang II has an effect opposite to that of
extracellular Ang II on vascular tone (9) suggesting an important
intracrine effect of the peptide on peripheral resistance. Further-
more, the (pro) renin receptor (PRR), mainly located intracellu-
larly (10, 11), is a new member of the RAS, originally considered
to be involved in the regulation of blood pressure. Recent observa-
tions using transgenic animals over-expressing PRR demonstrated
that PRR is an accessory protein of V-ATPase that plays an impor-
tant role in the regulation of several cellular homeostatic processes
including autophagy (11).
The harmful effects of Ang II on cardiovascular and renal sys-
tems inducing remodeling, seems, in part, related to increase in
oxidative stress. The discovery of angiotensin converting enzyme
2 (ACE2) (12) and the evidence that it promotes the formation of
Ang (1–7) from Ang II in animal models, represented an impor-
tant chapter in the studies of RAAS because Ang (1–7) counteracts
many effects of Ang II (13) including the enhancement of oxidative
stress induced by Ang II. Further studies are, however, necessary
to confirm if these beneficial effects of Ang (1–7) are present in
humans.
In this Research Topic, the pathophysiological role of local
RAAS in different tissues and organs are reviewed by different
authors, each one expert in their respective fields (14–18). We hope
these articles will help the development of future investigation of
this important topic.
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